An official American Thoracic Society/European Respiratory Society statement: Research questions in COPD

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 879-905

  Celli, Bartolome R ^b   Decramer, Marc ^b   Wedzicha, Jadwiga A ^b   Wilson, Kevin C ^a   Agustí, Alvar ^b   Criner, Gerard J ^b   MacNee, William ^b   Make, Barry J ^b   Rennard, Stephen I ^b   Stockley, Robert A ^b   Vogelmeier, Claus ^b   Anzueto, Antonio ^b   Au, David H ^b   Barnes, Peter J ^b   Burgel, Pierre Regis ^b   Calverley, Peter M ^b   Casanova, Ciro ^b   Clini, Enrico M ^b   Cooper, Christopher B ^b   Coxson, Harvey O ^b   Dusser, Daniel J ^b   Fabbri, Leonardo M ^b   Fahy, Bonnie ^b   Ferguson, Gary T ^b   Fisher, Andrew ^b   Fletcher, Monica J ^b   Hayot, Maurice ^b   Hurst, John R ^b   Jones, Paul W ^b   Mahler, Donald A ^b   Maltais, François ^b   Mannino, David M ^b   Martinez, Fernando J ^b   Miravitlles, Marc ^b   Meek, Paula M ^b   Papi, Alberto ^b   Rabe, Klaus F ^b   Roche, Nicolas ^b   Sciurba, Frank C ^b   Sethi, Sanjay ^b   Siafakas, Nikos ^b   Sin, Don D ^b   Soriano, Joan B ^b   Stoller, James K ^b   Tashkin, Donald P ^b   Troosters, Thierry ^b   Verleden, Geert M ^b   Verschakelen, Johny ^b   Vestbo, Jorgen ^b   Walsh, John W ^b   Washko, George R ^b   Wise, Robert A ^b   Wouters, Emiel F M ^b   ZuWallack, Richard L ^b   more..

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CANNABIS; CORTICOSTEROID DERIVATIVE; ELECTRONIC CIGARETTE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDACATEROL; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 5 ANTIBODY; LONG ACTING DRUG; MACROLIDE; MOXIFLOXACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE GUM; NICOTINE PATCH; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEINASE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TOXIC GAS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL RESPIRATORY SOUND; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; AVIATION; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREATHING RATE; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; COUGHING; COUNSELING; DIFFERENTIAL DIAGNOSIS; DIFFUSE PANBRONCHIOLITIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELECTRONIC MEDICAL RECORD; EMPHYSEMA; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; EXERCISE TEST; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GENETICS; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH STATUS; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HOME CARE; HOSPITALIZATION; HUMAN; INFLAMMATION; INTEGRATIVE MEDICINE; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; LUNG TRANSPLANTATION; LUNG VOLUME; MEDICAL INFORMATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MICROBIOME; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCORE; MONOTHERAPY; MORTALITY; NON INVASIVE PROCEDURE; NONINVASIVE MECHANICAL VENTILATION; NUTRITION; OCCUPATIONAL TOXICOLOGY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; OXYGEN SATURATION; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PHYSICAL EXAMINATION; PNEUMONIA; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESPIROMETRY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SELF CARE; SEX RATIO; SMOKING; SMOKING CESSATION; SOCIOECONOMICS; SPUTUM; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TERMINAL CARE; THORAX RADIOGRAPHY; TUBERCULOSIS; WALKING; WALKING SPEED; COMPARATIVE STUDY; DISEASE MANAGEMENT; EUROPE; FEMALE; MALE; ORGANIZATION AND MANAGEMENT; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SURVIVAL; UNITED STATES;

BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOCIETIES, MEDICAL; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84926435248     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00009015     Document Type: Article

References (277)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Miniño AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat Rep 2010; 59: 1-52.
3. López-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lancet Respir Med 2014; 2: 54-62.
4. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-457.
5. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368: 351-364.
6. Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013; 5: 235-245.
7. Celli BR, MacNee W, Agusti A, et al. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
8. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
9. O'Reilly J, Jones MM, Parnham J, et al. Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010; 340: c3134.
10. Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking-attributable morbidity in the United States. JAMA Intern Med 2014; 174: 1922-1928.
11. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43.
12. Jones P, Miravitlles M, van der Molen T, et al. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis 2012; 7: 697-709.
13. Roche N, Gaillat J, Garre M, et al. Acute respiratory illness as a trigger for detecting chronic bronchitis in adults at risk of COPD: a primary care survey. Prim Care Respir J 2010; 19: 371-377.
14. Cote CG, Casanova C, Marín JM, et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31: 571-578.
15. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
16. Coxson HO, Lam S. Quantitative assessment of the airway wall using computed tomography and optical coherence tomography. Proc Am Thorac Soc 2009; 6: 439-443.
17. Copley SJ, Wells AU, Müller NL, et al. Thin-section CT in obstructive pulmonary disease: discriminatory value. Radiology 2002; 223: 812-819.
18. Coxson HO, Mayo J, Lam S, et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 588-597.
19. Barr RG, Berkowitz EA, Bigazzi F, et al. COPDGene CT Workshop Group. A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 2012; 9: 151-159.
20. Galbán CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012; 18: 1711-1715.
21. Christe A, Charimo-Torrente J, Roychoudhury K, et al. Accuracy of low-dose computed tomography (CT) for detecting and characterizing the most common CT-patterns of pulmonary disease. Eur J Radiol 2013; 82: e142-e150.
22. Castaldi PJ, San José Estépar R, Mendoza CS, et al. Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med 2013; 188: 1083-1090.
23. Coxson HO, Leipsic J, Parraga G, et al. Using pulmonary imaging to move COPD beyond FEV1. Am J Respir Crit Care Med 2014; 190: 135-144.
24. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913-919.
25. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
26. Cerveri I, Corsico AG, Accordini S, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040-1045.
27. Bhatt SP, Sieren JC, Dransfield MT, et al. COPDGene Investigators. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction. Thorax 2014; 69: 409-414.
28. Carlsson AC, Wändell P, Ösby U, et al. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health 2013; 13: 670-678.
29. Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768-774.
30. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148: 529-534.
31. Ferrer M, Alonso J, Morera J, et al. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072-1079.
32. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-641.
33. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
34. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
35. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20.
36. Celli BR, Halbert RJ, Isonaka S, et al. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
37. Parshall MB, Schwartzstein RM, Adams L, et al. American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435-452.
38. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797.
39. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
40. Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 2009; 136: 1473-1479.
41. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
42. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778.
43. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
44. Cote CG, Pinto-Plata VM, Marin JM, et al. The modified BODE index: validation with mortality in COPD. Eur Respir J 2008; 32: 1269-1274.
45. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692-699.
46. Marin JM, Alfageme I, Almagro P, et al. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J 2013; 42: 323-332.
47. Celli BR, Locantore N, Yates J, et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065-1072.
48. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
49. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180: 1189-1195.
50. Almagro P, Soriano JB, Cabrera FJ, et al. Working Group on COPD, Spanish Society of Internal Medicine. Shortand medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest 2014; 145: 972-980.
51. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981.
52. Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest 2013; 143: 694-702.
53. Johannessen A, Nilsen RM, Storebø M, et al. Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med 2013; 188: 51-59.
54. Divo M, Cote C, de Torres JP, et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
55. Agustí A, Barberà JA, Wouters EFM, et al. Lungs, bone marrow, and adipose tissue. A network approach to the pathobiology of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1396-1406.
56. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
57. Vestbo J, Edwards LD, Scanlon PD, et al. ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-1192.
58. Agusti A, Calverley PM, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122-136.
59. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15-21.
60. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
61. Drazen JM, Fabbri LM. Ageing and multimorbidity. Eur Respir J 2014; 44: 557.
62. Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775-788.
63. Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44: 1055-1068.
64. Patel AR, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851-857.
65. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
66. Wilson DO, Leader JK, Fuhrman CR, et al. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the Pittsburgh lung screening study. J Thorac Oncol 2011; 6: 1200-1205.
67. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
68. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
69. Roca M, Verduri A, Corbetta L, et al. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013; 43: 510-521.
70. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097.
71. Bowler RP, Kim V, Regan E, et al. COPDGene Investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941-950.
72. Tan WC, Bourbeau J, Hernandez P, et al. CanCOLD Collaborative Research Group. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 2014; 69: 709-717.
73. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
74. Repine JE, Bast A, Lankhorst I. Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-357.
75. Tzortzaki EG, Siafakas NM. A hypothesis for the initiation of COPD. Eur Respir J 2009; 34: 310-315.
76. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
77. Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 2012; 7: e47305.
78. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
79. Demedts IK, Demoor T, Bracke KR, et al. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006; 7: 53.
80. Faner R, Rojas M, Macnee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 306-313.
81. Yang Q, Underwood MJ, Hsin MK, et al. Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008; 9: 661-667.
82. Rab A, Rowe SM, Raju SV, et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol 2013; 305: L530-L541.
83. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
84. Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S12-S16.
85. Peinado VI, Barberá JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
86. Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir Monogr 1998; 3: 107-126.
87. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
88. Matsuba K, Wright JL, Wiggs BR, et al. The changes in airways structure associated with reduced forced expiratory volume in one second. Eur Respir J 1989; 2: 834-839.
89. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.
90. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014; 370: 60-68.
91. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
92. Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336: 598-600.
93. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873.
94. Stratelis G, Mölstad S, Jakobsson P, et al. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006; 24: 133-139.
95. Kotz D, Wesseling G, Huibers MJH, et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33: 754-762.
96. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.
97. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
98. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599.
99. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-342.
100. Wagena EJ, van der Meer RM, Ostelo RJ, et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815.
101. Wilson I. Depression in the patient with COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 61-64.
102. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-229.
103. Kuehn BM. Updated US smoking cessation guideline advises counseling, combining therapies. JAMA 2008; 299: 2736.
104. Shah SD, Wilken LA, Winkler SR, et al. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003) 2008; 48: 659-665.
105. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009; 150: 447-454.
106. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66: 1253-1262.
107. Ellerbeck EF, Mahnken JD, Cupertino AP, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med 2009; 150: 437-446.
108. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guidelines. Rockville, US Department of Health and Human Services, 2008.
109. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology (Berl) 1995; 119: 193-204.
110. Etter J-F, Bullen C, Flouris AD, et al. Electronic nicotine delivery systems: a research agenda. Tob Control 2011; 20: 243-248.
111. Etter J-F, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction 2011; 106: 2017-2028.
112. Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey. Drug Alcohol Rev 2013; 32: 133-140.
113. Bertholon JF, Becquemin MH, Annesi-Maesano I, et al. Electronic cigarettes: a short review. Respiration 2013; 86: 433-438.
114. Schraufnagel DE, Blasi F, Drummond MB, et al. Forum of International Respiratory Societies. Electronic cigarettes: a position statement of the forum of international respiratory societies. Am J Respir Crit Care Med 2014; 190: 611-618.
115. Buist AS, Sexton GJ, Nagy JM, et al. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976; 114: 115-122.
116. Jiménez-Ruiz C, Solano S, Viteri SA, et al. Harm reduction - a treatment approach for resistant smokers with tobacco-related symptoms. Respiration 2002; 69: 452-455.
117. Rennard SI, Daughton D, Fujita J, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 1990; 3: 752-759.
118. Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011-1017.
119. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006; 8: 739-749.
120. Boyle R, Solberg L, Fiore M. Use of electronic health records to support smoking cessation. Cochrane Database Syst Rev 2011; 12: CD008743.
121. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167: 221-228.
122. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
123. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
124. Burgel PR, Paillasseur JL, Dusser D, et al. UPLIFT® Study Investigators. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res 2014; 15: 64.
125. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
126. Decramer M, Celli B, Kesten S, et al. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
127. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS ONE 2012; 7: e51048.
128. Bateman ED, Feldman C, O'Brien J, et al. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision. S Afr Med J 2004; 94: 559-575.
129. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012; 40: 1545-1554.
130. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189: 1503-1508.
131. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD009157.
132. Rabe KF, Fabbri LM, Israel E, et al. Effect of ADRB2 polymorphism on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2014; 2: 44-53.
133. Decramer ML, Chapman KR, Dahl R, et al. INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533.
134. Calverley PM, Stockley RA, Seemungal TA, et al. Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505-512.
135. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-647.
136. Wedzicha JA, Calverley PM, Seemungal TA, et al. INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
137. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
138. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
139. Short PM, Williamson PA, Elder DH, et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012; 141: 81-86.
140. Jung KS, Park HY, Park SY, et al. Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012; 106: 382-389.
141. Magnussen H, Disse B, Rodriguez-Roisin R, et al. WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294.
142. Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011; 66: 425-429.
143. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
144. Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012; 142: 134-140.
145. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 939-943.
146. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011; 105: 435-441.
147. Barnestein-Fonseca P, Leiva-Fernández J, Vidal-España F, et al. Efficacy and safety of a multifactor intervention to improve therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): protocol for the ICEPOC study. Trials 2011; 12: 40.
148. Melani AS, Bonavia M, Cilenti V, et al. Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930-938.
149. Vincken W, Dekhuijzen PR, Barnes P. ADMIT Group. The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010; 19: 10-20.
150. Laube BL, Janssens HM, de Jongh FHC, et al. European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1331.
151. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006; 7: 70.
152. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013; 12: 543-559.
153. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015-1026.
154. Rennard SI, Fogarty C, Kelsen S, et al. COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934.
155. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomized, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2: 891-901.
156. Chong J, Poole P, Leung B, et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 5: CD002309.
157. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472-478.
158. Lomas DA, Lipson DA, Miller BE, et al. Losmapimod Study Investigators. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52: 416-424.
159. Watz H, Barnacle H, Hartley BF, et al. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2: 63-72.
160. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-1917.
161. Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44: 789-791.
162. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
163. Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014; 11: 1011-1017.
164. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
165. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 139-148.
166. Yamaya M, Azuma A, Takizawa H, et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494.
167. Albert RK, Connett J, Bailey WC, et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
168. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
169. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1890.
170. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089-1096.
171. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-1712.
172. Sethi S, Jones PW, Theron MS, et al. PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.
173. Marin L, Colombo P, Bebawy M, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv 2011; 8: 1205-1220.
174. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85: 414-421.
175. Bando M, Miyazawa T, Shinohara H, et al. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 493-498.
176. Bartziokas K, Papaioannou AI, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther 2011; 24: 625-631.
177. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009; 136: 734-743.
178. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
179. Lee TM, Chen CC, Shen HN, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009; 116: 497-505.
180. Criner GJ, Connett JE, Aaron SD, et al. COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-2210.
181. Price LC, Lowe D, Hosker HS, et al. British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu). UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006; 61: 837-842.
182. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
183. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139: 165-173.
184. Spruit MA, Singh SJ, Garvey C, et al. ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
185. Vieira DS, Maltais F, Bourbeau J. Home-based pulmonary rehabilitation in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16: 134-143.
186. Maltais F, Bourbeau J, Shapiro S, et al. Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network, Fonds de recherche en santé du Québec. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149: 869-878.
187. van Wetering CR, Hoogendoorn M, Mol SJ, et al. Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010; 65: 7-13.
188. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 2010; 11: 179-187.
189. Puhan MA, Gimeno-Santos E, Scharplatz M, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 10: CD005305.
190. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.
191. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.
192. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-398.
193. Górecka D, Gorzelak K, Sliwiñski P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679.
194. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14: 1002-1008.
195. Petty TL, Stanford RE, Neff TA. Continuous oxygen therapy in chronic airway obstruction. Observations on possible oxygen toxicity and survival. Ann Intern Med 1971; 75: 361-367.
196. West GA, Primeau P. Nonmedical hazards of long-term oxygen therapy. Respir Care 1983; 28: 906-912.
197. Murabit A, Tredget EE. Review of burn injuries secondary to home oxygen. J Burn Care Res 2012; 33: 212-217.
198. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817-822.
199. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555-1557.
200. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799-1806.
201. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931-1935.
202. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet 2009; 374: 250-259.
203. Bhatt SP, Peterson MW, Wilson JS, et al. Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. Int J Chron Obstruct Pulmon Dis 2013; 8: 581-589.
204. Lamia B, Cuvelier A, Benichou J, et al. Bénéfices de la ventilation non invasive à domicile au décours d'une insuffisance respiratoire aiguë hypercapnique chez les patients BPCO. Étude contrôlée randomisée multicentrique. Étude Non Invasive Ventilation in Obstructive Lung Disease (Nivold) [A multi-centre randomised controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study]. Rev Mal Respir 2012; 29: 1141-1148.
205. Clini E, Sturani C, Rossi A, et al. Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-538.
206. Struik FM, Sprooten RT, Kerstjen HA, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax 2014; 69: 826-834.
207. Struik FM, Lacasse Y, Goldstein RS, et al. Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 2014; 108: 329-337.
208. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698-705.
209. Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease. Thorax 2003; 58: 634-638.
210. Fishman A, Martinez F, Naunheim K, et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073.
211. Ramsey SD, Berry K, Etzioni R, et al. National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003; 348: 2092-2102.
212. Sciurba FC, Ernst A, Herth FJ, et al. VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233-1244.
213. th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 1073-1086.
214. Thabut G, Ravaud P, Christie JD, et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1156-1163.
215. Lahzami S, Bridevaux PO, Soccal PM, et al. Survival impact of lung transplantation for COPD. Eur Respir J 2010; 36: 74-80.
216. Eskander A, Waddell TK, Faughnan ME, et al. BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation. J Heart Lung Transplant 2011; 30: 1334-1341.
217. Orens JB, Estenne M, Arcasoy S, et al. Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
218. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008; 371: 744-751.
219. Wang Q, Rogers CA, Bonser RS, et al. UK Cardiothoracic Transplant Steering Group. Assessing the benefit of accepting a single lung offer now compared with waiting for a subsequent double lung offer. Transplantation 2011; 91: 921-926.
220. Munson JC, Christie JD, Halpern SD. The societal impact of single versus bilateral lung transplantation for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 1282-1288.
221. Schols AM, Gosker HR. The pathophysiology of cachexia in chronic obstructive pulmonary disease. Curr Opin Support Palliat Care 2009; 3: 282-287.
222. Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94: 859-867.
223. Creutzberg EC, Schols AMWJ, Bothmer-Quaedvlieg FCM, et al. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998; 52: 396-401.
224. Hallin R, Janson C, Arnardottir RH, et al. Relation between physical capacity, nutritional status and systemic inflammation in COPD. Clin Respir J 2011; 5: 136-142.
225. Collins PF, Stratton RJ, Elia M. Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr 2012; 95: 1385-1395.
226. Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional support for individuals with COPD: a meta-analysis. Chest 2000; 117: 672-678.
227. Laveneziana P, Palange P. ERS Research Seminar Faculty. Physical activity, nutritional status and systemic inflammation in COPD. Eur Respir J 2012; 40: 522-529.
228. Hanson C, Rutten EP, Wouters EF, et al. Diet and vitamin D as risk factors for lung impairment and COPD. Transl Res 2013; 162: 219-236.
229. Bjerk SM, Edgington BD, Rector TS, et al. Supplemental vitamin D and physical performance in COPD: a pilot randomized trial. Int J Chron Obstruct Pulmon Dis 2013; 8: 97-104.
230. Bourbeau J, Julien M, Maltais F, et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585-591.
231. Hernandez C, Casas A, Escarrabill J, et al. CHRONIC project. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21: 58-67.
232. Garcia-Aymerich J, Hernandez C, Alonso A, et al. Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med 2007; 101: 1462-1469.
233. Casas A, Troosters T, Garcia-Aymerich J, et al. members of the CHRONIC Project. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006; 28: 123-130.
234. Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 890-896.
235. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012; 156: 673-683.
236. Ram FS, Wedzicha JA, Wright J, et al. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2004; 329: 315.
237. Seemungal TA, Wedzicha JA. Integrated care: a new model for COPD management? Eur Respir J 2006; 28: 4-6.
238. Vontetsianos T, Giovas P, Katsaras T, et al. Telemedicine-assisted home support for patients with advanced chronic obstructive pulmonary disease: preliminary results after nine-month follow-up. J Telemed Telecare 2005; 11: 86-88.
239. Vitacca M, Bianchi L, Guerra A, et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J 2009; 33: 411-418.
240. Sicotte C, Paré G, Morin S, et al. Effects of home telemonitoring to support improved care for chronic obstructive pulmonary diseases. Telemed J E Health 2011; 17: 95-103.
241. Pinnock H, Hanley J, McCloughan L, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ 2013; 347: f6070.
242. Knauft E, Nielsen EL, Engelberg RA, et al. Barriers and facilitators to end-of-life care communication for patients with COPD. Chest 2005; 127: 2188-2196.
243. Au DH, Udris EM, Fihn SD, et al. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med 2006; 166: 326-331.
244. Curtis JR, Engelberg RA, Nielsen EL, et al. Patient-physician communication about end-of-life care for patients with severe COPD. Eur Respir J 2004; 24: 200-205.
245. Au DH, Udris EM, Engelberg RA, et al. A randomized trial to improve communication about end-of-life care among patients with COPD. Chest 2012; 141: 726-735.
246. Claessens MT, Lynn J, Zhong Z, et al. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. J Am Geriatr Soc 2000; 48, Suppl. 5: S146-S153.
247. White P, White S, Edmonds P, et al. Palliative care or end-of-life care in advanced chronic obstructive pulmonary disease: a prospective community survey. Br J Gen Pract 2011; 61: e362-e370.
248. Janssen DJ, Spruit MA, Uszko-Lencer NH, et al. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011; 14: 735-743.
249. Gott M, Gardiner C, Small N, et al. Barriers to advance care planning in chronic obstructive pulmonary disease. Palliat Med 2009; 23: 642-648.
250. Janssen DJ, Curtis JR, Au DH, et al. Patient-clinician communication about end-of-life care for Dutch and US patients with COPD. Eur Respir J 2011; 38: 268-276.
251. Fleisher LA, Beckman JA, Brown KA, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: e418-e499.
252. Poldermans D, Bax JJ, Schouten O, et al. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006; 48: 964-969.
253. Poldermans D, Schouten O, Vidakovic R, et al. DECREASE Study Group. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol 2007; 49: 1763-1769.
254. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795-2804.
255. British Thoracic Society. Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56: 89-108.
256. nd edition). Chest 2007; 132: 161S-177S.
257. Mandra A, Simiæ D, Stevanoviæ V, et al. Preoperative considerations for patients with chronic obstructive pulmonary disease. Acta Chir Iugosl 2011; 58: 71-75.
258. Brunelli A, Refai M, Xiumé F, et al. Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection. Ann Thorac Surg 2008; 86: 240-247.
259. Win T, Tasker AD, Groves AM, et al. Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy. AJR Am J Roentgenol 2006; 187: 1260-1265.
260. Ferguson MK, Little L, Rizzo L, et al. Diffusing capacity predicts morbidity and mortality after pulmonary resection. J Thorac Cardiovasc Surg 1988; 96: 894-900.
261. Wang JS. Relationship of predicted postoperative product to postpneumonectomy cardiopulmonary complications. J Chin Med Assoc 2003; 66: 643-654.
262. Wang JS. Relationship of carbon monoxide pulmonary diffusing capacity to postoperative cardiopulmonary complications in patients undergoing pneumonectomy. Kaohsiung J Med Sci 2003; 19: 437-446.
263. Bolliger CT, Jordan P, Solèr M, et al. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med 1995; 151: 1472-1480.
264. Holden DA, Rice TW, Stelmach K, et al. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest 1992; 102: 1774-1779.
265. Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989; 139: 902-910.
266. Pierce RJ, Copland JM, Sharpe K, et al. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 1994; 150: 947-955.
267. Nakahara K, Monden Y, Ohno K, et al. A method for predicting postoperative lung function and its relation to postoperative complications in patients with lung cancer. Ann Thorac Surg 1985; 39: 260-265.
268. Nakahara K, Ohno K, Hashimoto J, et al. Prediction of postoperative respiratory failure in patients undergoing lung resection for lung cancer. Ann Thorac Surg 1988; 46: 549-552.
269. Taylor MD, LaPar DJ, Isbell JM, et al. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2014; 147: 738-744.
270. Brunelli A, Al Refai M, Monteverde M, et al. Predictors of early morbidity after major lung resection in patients with and without airflow limitation. Ann Thorac Surg 2002; 74: 999-1003.
271. Edvardsen A, Akerø A, Hardie JA, et al. High prevalence of respiratory symptoms during air travel in patients with COPD. Respir Med 2011; 105: 50-56.
272. Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2011; 66: i1-i30.
273. Seccombe LM, Peters MJ. Oxygen supplementation for chronic obstructive pulmonary disease patients during air travel. Curr Opin Pulm Med 2006; 12: 140-144.
274. Akerø A, Christensen CC, Edvardsen A, et al. Pulse oximetry in the preflight evaluation of patients with chronic obstructive pulmonary disease. Aviat Space Environ Med 2008; 79: 518-524.
275. Akerø A, Edvardsen A, Christensen CC, et al. COPD and air travel: oxygen equipment and preflight titration of supplemental oxygen. Chest 2011; 140: 84-90.
276. Abdool-Gaffar MS, Ambaram A, Ainslie GM, et al. COPD Working Group. Guideline for the management of chronic obstructive pulmonary disease - 2011 update. S Afr Med J 2011; 101: 63-73.
277. Christensen CC, Ryg MS, Edvardsen A, et al. Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients. Eur Respir J 2004; 24: 580-586.